A carregar...
CAR T-cell immunotherapy of B-cell malignancy: the story so far
Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies. Promising results from pivotal anti-CD19 CAR T-cell phase II trials have led to landmark approvals of two CD19-specific CAR T-cell pr...
Na minha lista:
| Publicado no: | Ther Adv Vaccines Immunother |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7257863/ https://ncbi.nlm.nih.gov/pubmed/32524070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2515135520927164 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|